MaxCyte’s use of twitter and social media
MaxCyte is a user of Twitter and other social media properties and maintains a corporate Twitter account using the screen name: @MaxCyte_Inc.
MaxCyte recognizes the importance of social media, including Twitter, and new communication channels that enable MaxCyte to engage in interactive discussion. As a development-stage biopharmaceutical company, MaxCyte is committed to abide by the legal, ethical and regulatory standards applicable to the Company. MaxCyte aims to have responsible social interactions.
MaxCyte may respond to questions and comments presented via Twitter and other social media properties, when appropriate. MaxCyte may not be able to immediately respond to questions or comments, and responses, if any, may be limited in nature.
There may be questions and/or comments MaxCyte cannot address, including, but not limited to, questions related to non-public confidential information, proprietary information, financial matters, ongoing legal matters, regulatory issues and other aspects of MaxCyte’s business. MaxCyte will not respond to rumors, personal attacks, foul language, disparaging comments or topics that do not relate directly to MaxCyte.
Twitter accounts that MaxCyte follows or is followed by do not indicate an endorsement of the account owner or their products and services.
MaxCyte may provide links or references to external websites, not controlled by MaxCyte, as part of its Tweets. However, MaxCyte does not endorse or claim responsibility for the content of such other websites. Any links or references to such external websites are provided as merely a convenience to the users of the Twitter platform.
MaxCyte reserves all rights relating to the MaxCyte Twitter account (@MaxCyte_Inc.) and its other social media properties including, but not limited to, all rights to add, remove or modify any content or material posted on the account, discontinue the account, accept or reject those who may wish to follow the account and respond to, or refrain from responding to, any questions or comments addressed to the account.
Learn about cutting-edge applications, new resources, and upcoming events.
Subscribe to our e-Newsletter